UK Markets closed

Formycon AG (FYB.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
54.00+0.20 (+0.37%)
At close: 11:45AM CEST
Full screen
Previous close53.80
Open54.00
Bid0.00 x 30000
Ask0.00 x 30000
Day's range54.00 - 54.00
52-week range27.00 - 79.80
Volume150
Avg. volume617
Market cap584.42M
Beta (5Y monthly)1.27
PE ratio (TTM)N/A
EPS (TTM)-0.30
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est54.75
  • EQS Group

    Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021

    DGAP-News: Formycon AG / Key word(s): Miscellaneous/Miscellaneous15.09.2021 / 08:40 The issuer is solely responsible for the content of this announcement.Press Release // September 15, 2021Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) yesterday received the Pharma Trend Image & Innovation "Most Innovative Product(R)" Award in the category of Leap Innovations for its COVID-19 drug development FYB20

  • EQS Group

    Formycon reports on the status of FYB207 development

    DGAP-News: Formycon AG / Key word(s): Scientific publication/Study11.08.2021 / 08:00 The issuer is solely responsible for the content of this announcement. Press Release // August 11, 2021Formycon reports on the status of FYB207 development- Efficient neutralization of SARS-CoV-2 variants-of-concern- Production for preclinical and clinical product established at fast track- Expansion of preclinical efficacy testing planned- Phase I/IIa clinical trial expected to start first half of 2022Munich -

  • EQS Group

    Formycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA)

    Formycon AG / Key word(s): Regulatory Admission/MiscellaneousFormycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA)05-Aug-2021 / 22:05 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Publi